Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea - Wikidata - wikimedia - TriplyDB

Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea

Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea

http://www.wikidata.org/entity/Q33385981

about

Sunitinib: the antiangiogenic effects and beyond Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.Pharmacokinetic/Pharmacodynamic Analysis of a Hemodialyzed Patient Treated with 25 mg of Sunitinib Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma.Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial.Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience.Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience.Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries Current status of targeted therapy for advanced renal cell carcinoma Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinoma Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients.Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience.Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain.Axitinib plasma pharmacokinetics and ethnic differences.Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.Kidney Cancer Working Group report.Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib.BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients.

P2860

Q28066499-2FFAA26D-F9A7-43DA-8FE8-0E93C183CDC8 Q28550377-72C04F17-871A-4264-8F0C-706290A8EC7D Q33392955-083ECE44-F7C1-4539-AA82-9063E203D5D9 Q33405028-130081D0-00AF-440F-B3CA-06C77E976335 Q33410008-C5EFD97C-841E-44EE-B7CA-EFB6D459C2D4 Q33410206-44862D8A-0EA9-4B1F-875C-3D7D3EECA4AF Q33419600-84B530C9-1DB0-4B4D-82FC-5F1B04D1908F Q33434845-CEB85360-E482-430E-870A-7089F3297305 Q33437427-735F1191-2ED1-43DF-B858-9DAED13C6993 Q33633431-0D0FE9A2-D674-4670-B6FB-66BE27040210 Q33931392-1B070F68-0C12-4595-919F-968C7E751464 Q34009449-834D54A8-29BD-4151-B2BC-8798A69659CD Q34193096-E9FFD2E3-3275-4206-BEE7-3A34338B8D31 Q34657590-EE1809B8-A54D-464F-9313-66F0E536DB9B Q34982554-7F993BBF-0634-4471-8A23-5328336FB2F7 Q35903850-CFEE7E84-A50E-41F7-BAC1-54752C11C84B Q36467394-A71EDA18-41B6-4602-A2D4-913FA422A5A0 Q36959106-DD4D583D-9F55-4E1B-8379-5C83314C6AA9 Q37387563-1B07DABA-EBC2-4501-A07B-D6497D9BE73B Q37500124-52BBEBBF-E9DF-432D-94C0-3B1F0CD3DB6F Q37650644-0A7B0BE7-0499-4846-AE78-EAD6B8A61DDB Q38004605-985C57B8-2E9F-4F16-A07A-A10B552351BE Q38091137-FC03C4A4-7053-4978-854A-1E4D7A8BFF15 Q38348548-4897E446-83D7-4645-8FA8-E4FFED0B66DC Q39348852-36830C1F-8DCA-48AD-AC4F-DFAEC814E562 Q42876509-26BC2ED4-DAC9-4D2B-B37A-6412F5FB96D2 Q45082802-B074CE20-0DD0-4BA7-BF59-E2D704143ADE Q50600192-13651323-243D-471D-BC4E-00442BD92837 Q53197402-3B029608-91F3-4535-8267-D1173527A691 Q55476332-51F7FCFE-31D2-4E44-951D-E592900B26AA

P2860

Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea

http://www.wikidata.org/entity/Q33385981

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Treatment outcomes of sunitini ...... cer center experience in Korea

@ast

Treatment outcomes of sunitini ...... cer center experience in Korea

@en

type

label

Treatment outcomes of sunitini ...... cer center experience in Korea

@ast

Treatment outcomes of sunitini ...... cer center experience in Korea

@en

prefLabel

Treatment outcomes of sunitini ...... cer center experience in Korea

@ast

Treatment outcomes of sunitini ...... cer center experience in Korea

@en

P1433

Q33385981-0D7081EC-D1AE-433E-9148-8ACB459FEC1E

P1476

Q33385981-665901BF-45C3-4167-8D14-88610F9D0DE9

P2093

Q33385981-18783A1A-EFAE-4EE1-AC6F-E1D6D6D0E0E7

Q33385981-2D7F414D-AE91-4144-8C02-F526BEBFFEBB

Q33385981-C56A0880-5FE5-4AEC-B3A3-04E70E567C70

Q33385981-ED230FE3-4606-4312-9CC5-FBCA063CA289

P2860

Q33385981-0F63DA55-A996-49E7-8F92-2D449774D6A0

Q33385981-0FC5D124-29E4-47FE-BC67-2E69B333B6BC

Q33385981-13507DF3-2D74-4837-B555-CAA0E11F6534

Q33385981-64466E23-60DD-4549-9C6E-80345AE8D6E0

Q33385981-67833ED0-1C7D-4763-BABB-44BD45790E30

Q33385981-9D731B77-9552-40FB-95A1-10297E9C18DC

Q33385981-A520DF27-8AE1-4448-AFC2-25A816BE2D58

Q33385981-B74F64D4-4D38-4741-BCA1-7D36FCD8A16F

Q33385981-BE2C2133-38DF-493F-A2BD-A48A48983C99

Q33385981-C38B5470-FD32-466B-81FE-8A98C1409EF1

P304

Q33385981-5F264084-FBB1-4656-BB44-91A484FF3D7B

P31

Q33385981-C33B92F2-4EC0-453D-8FF9-F7022E3FD8D0

P356

Q33385981-3C2BB3BE-C523-4EDC-A52C-99432D37A59F

P433

Q33385981-D0D9E515-1CF8-403B-B1E5-9543301DE634

P478

Q33385981-B92B9BD1-AC1F-43D1-9EA3-A23D57AA2ABA

P50

Q33385981-06DEC44E-C30C-463A-8A92-7CFCF0143C12

Q33385981-6C4B8DD1-C289-45EC-9A5B-58581238EA7C

Q33385981-831DFCE8-7023-467D-A4B5-503CD7606B17

Q33385981-95251D99-D5E5-4886-A7B5-2692FED52561

Q33385981-95E16D53-37D0-4BFE-BC1D-80749407E823

P577

Q33385981-4E19C3EE-6871-47CB-9037-592718EA1DC4

P5875

Q33385981-1CED1084-F624-4ABD-9294-364C88D16D05

P698

Q33385981-CE444192-50FF-48CF-A4AB-D4E4F4A2E24F

P932

Q33385981-83692BB5-781A-4606-B4F4-648DC9D8EAF6

P356

CRT.2009.41.2.67

P1433

Cancer Research and Treatment

P1476

Treatment outcomes of sunitini ...... cer center experience in Korea

@en

P2093

Chan Kim

http://www.w3.org/2001/XMLSchema#string

Hyo Song Kim

http://www.w3.org/2001/XMLSchema#string

Joong-Bae Ahn

http://www.w3.org/2001/XMLSchema#string

Jung Ryun Ahn

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

Cancer statistics, 2005

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Sunitinib in patients with metastatic renal cell carcinoma.

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.

Sunitinib: from rational design to clinical efficacy.

Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

P304

67-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4143/CRT.2009.41.2.67

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

Hyun Cheol Chung

P577

2009-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26767554

http://www.w3.org/2001/XMLSchema#string

P698

19707503

http://www.w3.org/2001/XMLSchema#string

P932

2731208

http://www.w3.org/2001/XMLSchema#string